Secukinumab

Drug Profile

Secukinumab

Alternative Names: AIN-457; Cosentyx; KB-03303A; NVP-AIN 457; Scapho

Latest Information Update: 23 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alcon; Novartis
  • Developer Icahn School of Medicine at Mount Sinai; Novartis
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis
  • Registered Pustular psoriasis
  • Phase III Psoriasis; Rheumatoid arthritis
  • Phase II Alopecia areata; Atopic dermatitis
  • Discontinued Asthma; Crohn's disease; Dry eyes; Multiple sclerosis; Polymyalgia rheumatica; Type 1 diabetes mellitus; Uveitis

Most Recent Events

  • 13 Sep 2017 Updated efficacy data from phase III extension A2304E1 trial released by Novartis
  • 31 Aug 2017 Novartis plans the SURPASS phase III trial for Ankylosing spondylitis (NCT03259074)
  • 06 Jul 2017 Committee for Medicinal Products for Human Use (CHMP) approves label updates for secukinumab in Psoriasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top